公开(公告)号：US20170360884A1

公开(公告)日：2017-12-21

申请号：US15537051

申请日：2015-12-29

Applicant: ACADEMIA SINICA

Inventor： Shie-Liang HSIEH ,  Yung-Chi CHANG ,  Ming-Ting HUANG

IPC: A61K38/17 ,  C07K14/705

CPC classification number: A61K38/177 ,  C07K14/70578 ,  C07K2319/30

Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.

公开(公告)号：US20210292413A1

公开(公告)日：2021-09-23

申请号：US17266092

申请日：2018-09-25

Applicant: Academia Sinica

Inventor： Shie-Liang HSIEH ,  Tsung-Yu TSAI ,  An-Suei YANG ,  Chung-Ming YU ,  Cheng-Yuan PENG

IPC: C07K16/28 ,  A61P31/20

Abstract: Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.

公开(公告)号：US20250136682A1

公开(公告)日：2025-05-01

申请号：US18837195

申请日：2023-04-01

Applicant: Academia Sinica

Inventor： Shie-Liang HSIEH ,  Pei-Shan SUNG ,  An-Suei YANG ,  Chung-Ming YU

IPC: C07K16/28 ,  A61K31/519 ,  A61K39/00 ,  A61K45/06 ,  A61P25/28 ,  A61P31/20 ,  A61P37/06

Abstract: Disclosed herein is generally directed to antibodies against the Siglec-3, and pharmaceutical compositions that comprise the antibodies. According to some embodiments of the present disclosure, the present anti-Siglec-3 antibodies may suppress the over activation of Siglec-3, thereby reversing the immunosuppression effects resulted therefrom. As such, the present antibodies may treat diseases associated with the over activation of Siglec-3, such as hepatitis B virus (HBV) infection, neurodegenerative diseases, autoimmune diseases, or cancers. Accordingly, the present disclosure also includes methods for the treatment and/or prophylaxis of the above diseases.

公开(公告)号：US20200010898A1

公开(公告)日：2020-01-09

申请号：US16491163

申请日：2018-03-15

Applicant: Academia Sinica

Inventor： Shie-Liang HSIEH ,  Ya-Lang HUANG ,  Tsung-Yu TSAI

IPC: C12Q1/6883 ,  G01N33/566 ,  G01N33/576 ,  C12Q1/70

Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.

公开(公告)号：US20230365640A1

公开(公告)日：2023-11-16

申请号：US18028747

申请日：2021-09-29

Applicant: Academia Sinica

Inventor： Shie-Liang HSIEH ,  Pei-Shan SUNG

IPC: C07K14/47 ,  A61P31/14 ,  A61P31/16

CPC classification number: C07K14/4726 ,  A61P31/14 ,  A61P31/16 ,  A61K38/00

Abstract: Disclosed herein is a CLEC2 fusion protein comprising a first polypeptide and a second polypeptide coupled to the upstream of the first polypeptide. According to embodiments of the present disclosure, the first and the second polypeptides respectively comprise the amino acid sequences of SEQ ID NOs: 1 and 2. Also disclosed therein are uses of the CLEC2 fusion protein in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treating influenza virus infection.

公开(公告)号：US20220213188A1

公开(公告)日：2022-07-07

申请号：US17269991

申请日：2019-09-25

Applicant: Academia Sinica

Inventor： Shie-Liang HSIEH ,  Pei-Shan SUNG ,  Ming-Ting HUANG ,  An-Suei YANG ,  Chung-Ming YU

IPC: C07K16/28 ,  A61P31/20 ,  A61P25/28

Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.